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We read with interest the recent article by Roth and 
colleagues [1] reporting the ﬁ  ndings of altered tumor-
speciﬁ  c microRNAs (miRNAs) in sera of breast cancer 
patients. Th   is report further substantiates emerging data 
suggesting that blood-based miRNAs have immense 
potential as novel non-invasive cancer biomarkers. 
However, we have several concerns regarding the authors’ 
study.
Roth and colleagues claim this article to be the ﬁ  rst 
evidence that circulating miRNAs have potential as 
breast cancer biomarkers, yet refer to previous reports of 
similar ﬁ  ndings [2,3]. Th   is aside, other claims in the study 
are unsubstantiated. Firstly, the ﬁ  nding that total RNA 
levels were signiﬁ  cantly higher in M0 patients compared 
to controls and M1 breast cancer patients most likely 
reﬂ  ects the quality of RNA extraction techniques and is 
not clinically relevant. We have previously demonstrated 
that total RNA levels diﬀ  er signiﬁ  cantly depending on the 
RNA isolation method and starting blood medium [2]. 
Th   e authors have not adequately discussed their ﬁ  nding 
that patients with metastatic disease had signiﬁ  cantly 
lower total RNA levels compared to M0 patients; if their 
claim that total RNA concentration indicated tumour 
progression held truth, then one would expect a 
sequential increase in total RNA concentration from 
controls, to M0 and M1 patients.
Th   e four candidate miRNAs (miR-10b, miR-34a,
miR-141, and miR-155) selected by Roth and colleagues 
for analysis is contentious. Evidence demonstrating con-
sis tent  diﬀ   erential expression of this miRNA panel in 
breast tumours, and functionality in breast tumour 
genesis and progression, is lacking. Given that currently 
1,212 mature human miRNAs have been identiﬁ  ed 
(miRBase, release 16 September 2010 [4]), and others 
strongly associated with breast cancer, there are more 
appropriate miRNAs worthy of consideration as breast 
cancer biomarkers.
Another concerning issue is the time-point at which 
serum samples were obtained from patients. Our group 
has previously demonstrated that circulating miRNAs 
that are elevated in breast cancer patients when the 
tumour is in situ (miR-195 and let-7a) decrease to basal 
levels by 2 weeks post-tumour resection. Whilst the half-
life of tumour-associated miRNAs in blood is undeﬁ  ned, 
ours and other studies would suggest that it is less than 
14 days [5]. Th   e authors’ samples were obtained from M0 
patients as late as 4 weeks post-operatively, at which time 
there would have been no disease, or at most microscopic 
foci, remaining. As the authors’ primary aim was to 
evaluate the feasibility of using circulating miRNAs for 
detection and staging of breast cancer, it would have been 
prudent to obtain blood samples pre-operatively.
We do believe that blood-based miRNA analysis has 
imminent clinical utility as tumour markers. However, if 
this concept is to translate readily from bench to bedside, 
then supporting data demonstrating feasibility and 
validity of this novel approach must stem from carefully 
planned and well-designed studies. If the current 
momentum in miRNA translational research can be 
maintained, then an era of non-invasive rapid diagnostics 
and individualized care for breast cancer patients is 
rapidly forthcoming.
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